Ankylosing Spondylitis Market Size, Share, Trends, Growth Outlook

Ankylosing Spondylitis Market is estimated to increase at a growth rate of 8.1% CAGR over the forecast period from 2024 to 2030.

The Ankylosing Spondylitis Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (NSAIDs, TNF inhibitors, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy).

An Introduction to Ankylosing Spondylitis Market in 2024

The Ankylosing Spondylitis Market in 2024 is experiencing notable growth, driven by the increasing prevalence of this chronic inflammatory condition, advancements in diagnostic techniques, and expanding treatment options to alleviate symptoms and improve patient outcomes. Ankylosing spondylitis is a type of arthritis that primarily affects the spine, causing pain, stiffness, and progressive fusion of the vertebrae. With advancements in disease understanding, targeted therapies, and biologic agents, the market offers a range of treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic therapies targeting inflammatory cytokines. Moreover, emerging research into novel therapeutic targets, personalized medicine approaches, and lifestyle interventions holds promise for further advancing treatment strategies and addressing the unmet needs of individuals living with ankylosing spondylitis.

Ankylosing Spondylitis Market Trend: Advancements in Biologic Therapies and Targeted Treatment Approaches

An emerging trend in the Ankylosing Spondylitis market is the rapid development and adoption of biologic therapies and targeted treatment approaches. With increasing understanding of the pathophysiology of ankylosing spondylitis (AS) and the pivotal role of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) in disease progression, there has been a surge in the development of biologic agents targeting these specific pathways. Additionally, novel therapeutic modalities such as Janus kinase (JAK) inhibitors and interleukin-23 (IL-23) inhibitors are being investigated for their efficacy in managing AS symptoms and slowing disease progression. These advancements offer promising alternatives for patients with refractory or intolerant disease, driving the market towards personalized and targeted treatment strategies.

Ankylosing Spondylitis Market Driver: Increasing Prevalence and Diagnostic Awareness

A significant driver fueling the Ankylosing Spondylitis market is the increasing prevalence of AS worldwide coupled with heightened diagnostic awareness among healthcare professionals. AS, a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, is being recognized more frequently, leading to earlier diagnosis and intervention. Factors such as genetic predisposition, environmental triggers, and improved diagnostic techniques such as magnetic resonance imaging (MRI) and human leukocyte antigen-B27 (HLA-B27) testing contribute to the growing identification of AS cases. As a result, there is a rising demand for effective pharmacological interventions and holistic management approaches to address the unmet medical needs of AS patients, thereby propelling market growth.

Ankylosing Spondylitis Market Opportunity: Expanding Treatment Pipeline and Therapeutic Innovation

An opportunity in the Ankylosing Spondylitis market lies in the expanding treatment pipeline and therapeutic innovation aimed at addressing the diverse needs of AS patients. With ongoing research efforts focused on unraveling the complex pathogenesis of AS and identifying novel therapeutic targets, there is a fertile ground for the development of innovative treatment modalities beyond conventional disease-modifying antirheumatic drugs (DMARDs) and biologic agents. Opportunities exist for pharmaceutical companies and biotechnology firms to invest in the discovery and development of next-generation therapies with improved efficacy, safety profiles, and modes of administration. Additionally, there is potential for collaboration and partnership between industry stakeholders, academic institutions, and patient advocacy groups to accelerate the translation of preclinical research findings into clinically meaningful treatments and advance the standard of care for AS patients.

Ankylosing Spondylitis Market Segmentation

By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Ankylosing Spondylitis Market Companies

AbbVie Inc
Amgen Inc
Eli Lilly and Company
Gilead Sciences
Janssen Pharmaceuticals
Merck & Co. Inc
Novartis AG
Pfizer Inc
Reliance Life Sciences Pvt. Ltd
UCB Inc

 

 

Reasons to Buy the Ankylosing Spondylitis Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Ankylosing Spondylitis Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Ankylosing Spondylitis Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Ankylosing Spondylitis Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Ankylosing Spondylitis Market Size Outlook, $ Million, 2021 to 2030
3.2 Ankylosing Spondylitis Market Outlook by Type, $ Million, 2021 to 2030
3.3 Ankylosing Spondylitis Market Outlook by Product, $ Million, 2021 to 2030
3.4 Ankylosing Spondylitis Market Outlook by Application, $ Million, 2021 to 2030
3.5 Ankylosing Spondylitis Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Ankylosing Spondylitis Market Industry
4.2 Key Market Trends in Ankylosing Spondylitis Market Industry
4.3 Potential Opportunities in Ankylosing Spondylitis Market Industry
4.4 Key Challenges in Ankylosing Spondylitis Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Ankylosing Spondylitis Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Ankylosing Spondylitis Market Outlook By Segments
7.1 Ankylosing Spondylitis Market Outlook by Segments
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

8 North America Ankylosing Spondylitis Market Analysis And Outlook To 2030
8.1 Introduction to North America Ankylosing Spondylitis Markets in 2024
8.2 North America Ankylosing Spondylitis Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Ankylosing Spondylitis Market size Outlook by Segments, 2021-2030
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

9 Europe Ankylosing Spondylitis Market Analysis And Outlook To 2030
9.1 Introduction to Europe Ankylosing Spondylitis Markets in 2024
9.2 Europe Ankylosing Spondylitis Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Ankylosing Spondylitis Market Size Outlook By Segments, 2021-2030
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

10 Asia Pacific Ankylosing Spondylitis Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Ankylosing Spondylitis Markets in 2024
10.2 Asia Pacific Ankylosing Spondylitis Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Ankylosing Spondylitis Market size Outlook by Segments, 2021-2030
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

11 South America Ankylosing Spondylitis Market Analysis And Outlook To 2030
11.1 Introduction to South America Ankylosing Spondylitis Markets in 2024
11.2 South America Ankylosing Spondylitis Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Ankylosing Spondylitis Market size Outlook by Segments, 2021-2030
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

12 Middle East And Africa Ankylosing Spondylitis Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Ankylosing Spondylitis Markets in 2024
12.2 Middle East and Africa Ankylosing Spondylitis Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Ankylosing Spondylitis Market size Outlook by Segments, 2021-2030
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Amgen Inc
Eli Lilly and Company
Gilead Sciences
Janssen Pharmaceuticals
Merck & Co. Inc
Novartis AG
Pfizer Inc
Reliance Life Sciences Pvt. Ltd
UCB Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy